OKYO Pharma Ltd ADR is a London-based preclinical biopharmaceutical company focused on developing innovative therapies for inflammatory eye diseases and ocular pain. The company is advancing a strategically prioritized pipeline that aims to address significant unmet medical needs in the ophthalmology sector, positioning itself for growth within this specialized market. With a commitment to scientific excellence and rigorous research, OKYO Pharma is poised to enhance the quality of life for patients suffering from challenging eye conditions through its cutting-edge therapeutics. Show more
Location: 14/15 CONDUIT ST, LONDON, UNITED KINGDOM, W1S 2XJ, London, W1S 2XJ, USA | Website: https://okyopharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
89.89M
52 Wk Range
$1.01 - $3.35
Previous Close
$1.90
Open
$1.82
Volume
64,974
Day Range
$1.82 - $1.98
Enterprise Value
75.05M
Cash
4.22M
Avg Qtr Burn
-1.528M
Insider Ownership
39.37%
Institutional Own.
6.69%
Qtr Updated
06/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Urcosimod (OK-101) Details Neuropathic Corneal Pain (NCP) | Phase 2b Initiation |
